logo-loader
viewCytoDyn Inc.

Full interview: CytoDyn reveals positive data on metastatic triple-negative breast cancer trial

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive it has released additional early Phase 1b/2 clinical trial results of its lead drug leronlimab in patients with CCR5 metastatic triple-negative breast cancer. Pourhassan says representatives from its lab called him crying, revealing the patient's tumor had shrunk. Pourhassan says data from the first patient enrolled show no detectable circulating tumor cells (CTC) in the peripheral blood with additional reductions in CCR5 expression on cancer-associated cells at eight weeks.

Quick facts: CytoDyn Inc.

Price: 0.305 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $118.42 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn offers update on leronlimab following encouraging...

CytoDyn Inc. (OTCQB:CYDY) CEO Nader Pourhassan and IncellDx Inc CEO Dr Bruce Patterson offer an update on leronlimab's mechanism of action (MOA) in regards to its ongoing cancer trials, specifically in metastatic breast cancer. Dr Patterson says the amazing thing about CCR5 is how it plays...

5 days, 13 hours ago

2 min read